Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Molecular Docking, Synthesis and anti-HIV-1 Protease Activity of Novel Chalcones

Author(s): Nemanja Turkovic, Branka Ivkovic*, Jelena Kotur-Stevuljevic, Milica Tasic, Bojan Marković and Zorica Vujic

Volume 26, Issue 8, 2020

Page: [802 - 814] Pages: 13

DOI: 10.2174/1381612826666200203125557

Price: $65

Abstract

Background: Since the beginning of the HIV/AIDS epidemic, 75 million people have been infected with the HIV and about 32 million people have died of AIDS. Investigation of the molecular mechanisms critical to the HIV replication cycle led to the identification of potential drug targets for AIDS therapy. One of the most important discoveries is HIV-1 protease, an enzyme that plays an essential role in the replication cycle of HIV.

Objective: The aim of the present study is to synthesize and investigate anti-HIV-1 protease activity of some chalcone derivatives with the hope of discovering new lead structure devoid drug resistance.

Methods: 20 structurally similar chalcone derivatives were synthesized and their physico-chemical characterization was performed. Binding of chalcones to HIV-1 protease was investigated by fluorimetric assay. Molecular docking studies were conducted to understand the interactions.

Results: The obtained results revealed that all compounds showed anti-HIV-1 protease activity. Compound C1 showed the highest inhibitory activity with an IC50 value of 0.001 μM, which is comparable with commercial product Darunavir.

Conclusion: It is difficult to provide general principles of inhibitor design. Structural properties of the compounds are not the only consideration; ease of chemical synthesis, low molecular weight, bioavailability, and stability are also of crucial importance. Compared to commercial products the main advantage of compound C1 is the ease of chemical synthesis and low molecular weight. Furthermore, compound C1 has a structure that is different to peptidomimetics, which could contribute to its stability and bioavailability.

Keywords: HIV, HIV-1 protease, inhibitors, chalcones, anti-HIV-1 protease activity, molecular docking.

« Previous Next »
[1]
Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220(4599): 868-71.
[http://dx.doi.org/10.1126/science.6189183] [PMID: 6189183]
[2]
UCSF Chimera v1. (resource for biocomputing, visualization, and informatics). Available at:. https://www.unaids.org/en
[3]
Ghosh AK, Osswald HL, Prato G. Recent progress in the development of hiv-1 protease inhibitors for the treatment of HIV/AIDS. J Med Chem 2016; 59(11): 5172-208.
[http://dx.doi.org/10.1021/acs.jmedchem.5b01697] [PMID: 26799988]
[4]
Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) 2015; 7: 95-104.
[PMID: 25897264]
[5]
Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 1999; 65(4): 337-53.
[http://dx.doi.org/10.1016/S0024-3205(99)00120-4] [PMID: 10421421]
[6]
McConkey BJ, Sobolev V, Edelman M. The performance of current methods in ligand-protein docking. Curr Sci 2002; 83: 845-55.
[7]
Weber IT, Kneller DW, Wong-Sam A. Highly resistant HIV-1 proteases and strategies for their inhibition. Future Med Chem 2015; 7(8): 1023-38.
[http://dx.doi.org/10.4155/fmc.15.44] [PMID: 26062399]
[8]
Gaber R, Majerle A, Jerala R, Benčina M. Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry. Sensors (Basel) 2013; 13(12): 16330-46.
[http://dx.doi.org/10.3390/s131216330] [PMID: 24287545]
[9]
Mateeva N, Eyunni SVK, Redda KK, et al. Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties. Bioorg Med Chem Lett 2017; 27(11): 2350-6.
[http://dx.doi.org/10.1016/j.bmcl.2017.04.034] [PMID: 28442256]
[10]
Wan Z, Hu D, Li P, Xie D, Gan X. Synthesis, antiviral bioactivity of novel 4-thioquinazoline derivatives containing chalcone moiety. Molecules 2015; 20(7): 11861-74.
[http://dx.doi.org/10.3390/molecules200711861] [PMID: 26132908]
[11]
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010; 31(2): 455-61.
[PMID: 19499576]
[12]
2005. ChemOffice Ultra 7.0. CambridgeSoft Corporation. Available at:. http://www.cambridgesoft.com
[13]
Chimera UCSF. Discovery studio visualizer. 2017.Available at:. http://www.cgl.ucsf. edu/chimera2006
[14]
2017.http://accelrys. com/products/collaborative-science/biovia-discovery-studio/ visualization-download.php
[15]
Jares-Erijman EA, Jovin TM. FRET imaging. Nat Biotechnol 2003; 21(11): 1387-95.
[http://dx.doi.org/10.1038/nbt896] [PMID: 14595367]
[16]
Zhengtong L, Yuan C, Yong W. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV/AIDS - Res. Palliat Care 2015; 7: 95-104.
[17]
Awasthi SK, Mishra N, Kumar B, et al. Potent antimalarial activity of newly synthesized substituted chalcone analogs in vitro. Med Chem Res 2009; 18: 407-20.
[http://dx.doi.org/10.1007/s00044-008-9137-9]
[18]
Cheng MS, Shili R, Kenyon G. A solid phase synthesis of chalcones by claisen-schmidt condensations. Chin Chem Lett 2000; 11: 851-4.
[19]
Ivković BM, Nikolić K, Ilić BB, et al. Phenylpropiophenone derivatives as potential anticancer agents: synthesis, biological evaluation and quantitative structure-activity relationship study. Eur J Med Chem 2013; 63: 239-55.
[http://dx.doi.org/10.1016/j.ejmech.2013.02.013] [PMID: 23501110]
[20]
Mager PP. The active site of HIV-1 protease. Med Res Rev 2001; 21(4): 348-53.
[http://dx.doi.org/10.1002/med.1012] [PMID: 11410934]
[21]
Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 1998; 27: 249-84.
[http://dx.doi.org/10.1146/annurev.biophys.27.1.249] [PMID: 9646869]
[22]
Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53(1): 4-9.
[http://dx.doi.org/10.1093/jac/dkh029] [PMID: 14657084]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy